NORWOOD, Mass. — December 18, 2025 — Leads & Copy — MariMed Inc. (CSE: MRMD) (OTCQX: MRMD) CEO Jon Levine issued a statement commending President Trump and his administration for reclassifying cannabis as a Schedule III drug. Levine stated this is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come.
The reclassification signifies the Federal government’s official acknowledgement that cannabis has widely accepted medical uses and low abuse potential, according to Levine.
Rescheduling will accelerate accredited medical research into medications derived from cannabis and should result in a significant increase of consumers who will embrace cannabis as a qualified alternative to opioids for chronic pain, sleep, anxiety and other ailments, said Levine.
Levine added that state-legal cannabis businesses will no longer be subject to the IRS Section 280E tax penalty and compliant operators like MariMed will finally be taxed like other consumer packaged goods sectors, materially improving profitability and free cash flow.
MariMed Inc. is a multi-state cannabis operator, known for developing and managing cultivation, production, and retail facilities. Its portfolio of cannabis brands includes Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™.
Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007
Source: MariMed Inc.
